Glioblastomas (GBMs) are the most common and aggressive type of brain tumor. GBMs usually show hyperactivation of the PI3K-Akt pathway, a pro-tumorigenic signaling cascade that contributes to pathogenesis. Girdin, an actin-binding protein identified as a novel substrate of Akt, regulates the sprouting of axons and the migration of neural progenitor cells during early postnatal-stage neurogenesis in the hippocampus. Here, we show that Girdin is highly expressed in human glioblastoma (GBM). Stable Girdin knockdown in isolated GBM stem cells resulted in decreased expression of stem cell markers, including CD133, induced multilineage neural differentiation, and inhibited in vitro cell motility, ex vivo invasion, sphere-forming capacity and in vivo tumor formation. Furthermore, exogenous expression of the Akt-binding domain of Girdin, which competitively inhibits its Akt-mediated phosphorylation, diminished the expression of stem cell markers, SOX2 and nestin, and migration on the brain slice and induced the expression of neural differentiation markers glial fibrillary acidic protein/bIII Tubulin. Our results reveal that Girdin is required for GBM-initiating stem cells to sustain the stemness and invasive properties.
Introduction
A subset of glioblastoma (GBM) tumor cells-cancer stem cells or tumor-initiating cells-are functionally defined by sustained self-renewal and the formation of phenocopies of parental tumors (Hemmati et al., 2003; Singh et al., 2004) , and are relatively resistant to radiotherapy and chemotherapy (Bao et al., 2006) .
Although the exact role of cancer stem cells in therapeutic resistance has not been defined, the identification of a tumor-cell subpopulation with enhanced capacity to promote tumor growth, angiogenesis and metastasis may elucidate cancer biology, which holds promise for the development of therapeutics for GBMs.
In malignant gliomas, Akt is a potential molecular target for angiogenesis, pathogenesis, apoptosis and invasion (Castellino and Durden, 2007) . Further, Aktpathway activation can induce the conversion of human anaplastic astrocytoma to human GBM (Sonoda et al., 2001) , and the PI3K-Akt pathway mediates cell survival and growth in GBM cells by phosphorylation-mediated regulation of multiple substrates (Datta et al., 1999; Brazil et al., 2002; Vivanco and Sawyers, 2002) .
Human Girdin (girders of actin filaments, previously designated as KIAA1212), which is encoded by the CCDC88A gene, is a novel actin cytoskeleton-binding protein recently identified as a substrate of the serine/ threonine kinase Akt1 (Enomoto et al., 2005) . In cultured fibroblasts and endothelial cells, Girdin functions in the remodeling of actin filaments in the lamellipodia at the leading edges of migrating cells (Enomoto et al., 2005) and sprouting of new blood vessels during development of the postnatal brain cortex (Kitamura et al., 2008) . Recently, Girdin was found to have a role in neurogenesis in the dentate gyrus, both postnatally and constitutively throughout adult life (Enomoto et al., 2009; Kim et al., 2009) . Girdin is highly expressed in immature progenitor cells that differentiate from neural stem cells in the subgranular zone of the dentate gyrus, and regulates the migration and positioning of newborn dentate granule cells. Thus, the function of Girdin is important for the physiology of neural stem cells in postnatal and adult brains, leading us to speculate that it has a role in the maintenance, migration, invasion and differentiation of brain-tumor stem cells (BTSCs).
This study was based on our hypothesis that the maintenance of GBM stem cells is dependent on Girdin.
Results

Girdin is strongly expressed in grade IV GBM
Girdin is a novel Akt substrate that is expressed in various types of human cancers (Jiang et al., 2008) .
To ascertain the expression of Girdin in human gliomas, we performed immunohistochemical staining with antiGirdin antibodies in 37 histologically confirmed glioma specimens (WHO grades II-IV). The cytoplasm of the tumor cells showed positive staining for Girdin ( Figure 1a) . We evaluated the Girdin-positive index for each sample. Girdin was highly expressed in grade IV tumors significantly (Figure 1b) , and real-time quantitative PCR (qPCR) confirmed this finding ( Figure 1c) . Thus, Girdin expression was strongly associated with tumor grade. Phosphorylated Girdin was hererogenously stained in Grade IV tumors, but not in the normal tissue, although there was no background staining with an isotype control IgG (Figure 1d ).
Association of Girdin and CD133 expressions in GBM stem cells
From GBM tissues, we previously established two neurosphere-like tumor cell lines (BTSCs or GBM stem cells) that could be maintained in serum-free neurobasal media for at least 2 months. Both lines (0222-and 0125-BTSCs) formed tumors in the brains of NOD-SCID mice even at 10 3 cells. We confirmed the expression of Girdin, the phosphorylation of Akt and the expression of the Akt regulator phosphatase and tensin homolog (PTEN) in both BTSC lines (Figure 2a) .
A number of reports have shown that brain tumors originate from CD133 þ cancer stem-like cells that recapitulate the self-renewal and multilineage-differentiation characteristics of the original tumor (Hemmati et al., 2003; Singh et al., 2004) . We sorted the CD133 þ and CD133-cells from the BTSC neurospheres using magnetic microbeads. Conventional and real-time qPCR revealed that Girdin expression was higher in CD133 þ cells than in CD133À cells (Figure 2b) . In order to exclude bias due to long-term in vitro culture, we also sorted CD133 þ and CD133À cells from two freshly dissociated tumors and quantified the level of Girdin (acutely-prepared 1228-BTSCs and 0323-BTSCs). The CD133À population in these two cell lines showed B30% of the Girdin expression level in CD133 þ population. Previously, Matsumoto et al. (2009) and Soeda et al. (2009) demonstrated that hypoxia (1% oxygen) induced the CD133 expression and propagated CD133 þ BTSCs by activating the EGFR/PI3K/Akt and Akt/mTOR/HIF1a signaling pathways. Consistent with this finding, the spheres proliferated faster and CD133 expression was induced in the two types of BTSCs cultured in hypoxic Stemness-maintaining function of Girdin in GBM stem cells A Natsume et al conditions for 2 weeks. Notably, the expression of Girdin was upregulated in parallel with that of CD133 under hypoxic conditions (Figure 2c ).
Girdin depletion induces differentiation from GBM stem cells
To determine the role of Girdin in GBMs, 0222-BTSCs and 0125-BTSCs were infected with a retrovirus harboring either control or Girdin short hairpin RNAs (shRNAs), and several independent stable clones were isolated. In the Girdin shRNA-expressing cells, Girdin depletion was confirmed by conventional RT-PCR, real-time qPCR, and western blot (Figures 3a and e) . First, to screen potential pathways that may be regulated by Girdin depletion (See the supplementary materials and methods), we performed gene-expression profiling, and genes upregulated >2-fold were analyzed by gene ontology (GO). GO terms including development, migration and locomotion were significantly affected (Supplementary Tables 2-6 , and Supplementary Figure S1 ). To better understand cell fates after Girdin knockdown, we analyzed the expression of stem cell genes (that is, OCT-4, SOX2 and nestin) and neuraldifferentiation markers (glial fibrillary acidic protein (GFAP), oligodendrocyte-specific protein and bIIItubulin). Even in serum-free medium, Girdin knockdown was accompanied by a dramatic reduction in stem cell gene expression and induction of neural-differentiation markers (Figures 3b and c) . Notably, depletion of Girdin significantly affected CD133/PROM-1 expression ( Figure 3c ). Immunocytochemistry demonstrated that Girdin was strongly expressed in the edge of BTSC cellular membranes and that it co-localized with b-actin. Girdin knockdown did not suppress the expression of bactin, whereas CD133 was remarkably suppressed in the Girdin shRNA-expressing cells (Figure 3d ). Western blot confirmed these results at the protein level ( Figure 3e ). These observations suggest that Girdin is required to inhibit differentiation of the CD133 þ stem cell population.
Girdin is required for directional migration and invasion of GBM stem cells The invasiveness of malignant gliomas complicates their complete surgical resection. Although the mechanisms underlying brain-tumor invasion have not been fully elucidated, the PI3K-Akt axis has been recognized as a contributor. CD133 þ cells also contribute to invasion and migration (Eyler et al., 2008; Gunther et al., 2008; Wakimoto et al., 2009) . GBM stem cell transplantation generates tumors that phenocopy the infiltrative features of the parental human GBM tumor (Singh et al., 2004; Lee et al., 2006; Yuki et al., 2009 ). Thus, Akt-mediated invasion is one of the prominent characteristics of BTSCs. Girdin functions in actin remodeling at the leading edge of migrating cells (Enomoto et al., 2005) , and migration and positioning of neural stem cells in the dentate gyrus of the hippocampus during the early postnatal period (Enomoto et al., 2009) . Therefore, we aimed to investigate the possible influence of Girdin depletion on the migratory capability of GBM cells.
To examine the effect of Girdin on cell migration in gliomas, we measured cell motility using the Boydenchamber assay. The cells with reduced Girdin expression moved less than control cells (Figure 4a ). To evaluate the effects of Girdin on cell motility under other physiological conditions, we examined the migration areas of BTSCs transfected with either Girdin shRNA or control shRNA on an organotypic mouse brain slice. We implanted a single CM-DiI-labeled BTSC Inhibition of the Akt-Girdin pathway resulted in a loss of maintenance of GBM stem cell properties Girdin is a large 250 kDa protein with unique aminoand carboxyl-terminal domains flanking a long coiled-coil domain. Girdin oligomerization through the amino-terminal domain and direct binding to actin filaments through the carboxyl-terminal domain are prerequisites for Girdin-mediated remodeling of the actin cytoskeleton at the leading edge of migrating cells (Enomoto et al., 2005) . Akt phosphorylates a serine residue at 1416 in the CT1 domain ( Figure 5a ). To elucidate the role of Girdin as an Akt substrate in BTSCs, we constructed a retroviral vector expressing the GFP (green fluorescent protein)-tagged CT1 domain of Girdin for competitive inhibition of the Akt-Girdin axis, and established a BTSC line that stably expresses GFP-CT1 ( Figure 5b ). As shown in Figure 5c , Girdin phosphorylation was significantly reduced in BTSCs transfected with the GFP-CT1 retrovirus, in comparison with cells transfected with control GFP retrovirus.
Further, we confirmed that the competitive inhibitor, GFP-CT1 did not inhibit phosphorylation of other targets of Akt besides Girdin, c-Raf and GSK-3b ( Figure 5d ).
In the GFP-CT1-expressig BTSCs, the expression of stem cell markers, SOX2 and nestin, was diminished, and the expression of GFAP and bIII-tubulin was significantly induced in BTSCs transfected with the GFP-CT1 retrovirus. The findings were consistent with those in Girdin deletion ( Figure 5d ). Further, the control GFP-BTSCs actively spread on a mouse brain slice, unlike the GFP-CT1-BTSCs, which showed very little invasion ( Figure 5e ). Taken together, these results indicate that inhibition of the Akt-Girdin pathway results in a loss of maintenance of brain tumor stem cell properties. 
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Girdin is required for brain-tumor formation in xenografts
In a tumorsphere formation assay, tumorsphere formation of Girdin-knockdown BTSCs was severely retarded in comparison with control BTSCs by 6-week culture in NBE media although all the cells remained viable (Figure 6a ). To investigate the potential effects of Girdin knockdown on the in vivo growth of BTSCs, glioma xenografts were produced in NOD/SCID mice with intracranial transplantation of Girdin-knockdown BTSCs or control BTSCs (0222-BTSCs and 0125-BTSCs). All mice transplanted with control BTSCs developed large tumor masses showing characteristic GBM features; these individuals died 5-9 weeks and 15-25 weeks post injection of 0125-BTSCs and 0222-BTSCs, respectively. In contrast, tumor formation was not observed in 9 of 10 mice transplanted with Girdin shRNA-expressing BTSCs ( Figure 6b) ; in the single individual where a tumor did develop, it was in the form of small, well-demarcated lesions (Figure 6c ). To rule out the possibility that cell motility, sphere formation and tumor formation may be affected by the change in proliferation rate, we counted cell number of Girdin-shRNA BTSCs and control BTSCs (Figure 6d ). The data show no apparent defects of cell proliferation in Girdin-shRNA BTSCs compared with control BTSCs, suggesting no evidence of the involvement of Girdin in cell cycle progression.
Discussion
The intracellular-signaling pathway mediated by PI3K-Akt pathway has a pivotal role in the progression of cancers (Luo et al., 2003; Wendel et al., 2004; Hay, 2005; Hennessy et al., 2005) . Akt has a wide range of substrates; the activation of Akt and its substrates regulates many important cellular functions, such as cell survival, growth, proliferation, metabolism, migration and invasion (Zhang et al., 2009) . The novel Akt substrate, Girdin, binds to the actin cytoskeleton (Enomoto et al., 2005) and both the expression and phosphorylation of Girdin are important in the progression of some types of cancer (Jiang et al., 2008) , postnatal angiogenesis of immature endothelial cells (Kitamura et al., 2008) and neurogenesis of neural progenitor cells (Enomoto et al., 2009) . These findings suggest that Girdin may be involved in the function of We found the highest frequency of Girdin positivity and phosphorylation in grade IV tumors (GBM) (Figures 1b  and c) . In solid tumors, CD133 þ cells represent a small subpopulation of cells with the capability to recapitulate the original tumor when serially transplanted in SCID mice and to self-renew and differentiate into mature phenotypes lacking stem cell-like properties. Evidence suggests that these cells are involved in tumor progression and invasion (Hermann et al., 2007) . In this study, we showed that Girdin was strongly expressed in CD133 þ GBM stem cells. Girdin knockdown reduced the expression of CD133 and promoted differentiation into mature phenotypes. These findings were reproducible even when another Girdin shRNA was used against a different region (Supplementary Figure 2A ). Interestingly, Girdin knockdown also resulted in a change in the phenotype of human neural stem cells (Supplementary Figure 2B , and see also the supplementary information). Further research is needed to elucidate the molecular basis of this cooperative regulation.
Girdin was first identified as an Akt substrate, although it has been suggested that Girdin functions upstream of Akt to augment its activity, which in turn regulating apoptosis and DNA synthesis (Anai et al., 2005) . Moreover, Girdin associates with the plasma membrane through its CT1 domain. In vitro binding assays have shown that the purified recombinant CT1 domain of Girdin specifically binds to membrane-bound phosphoinositides PI(4)P and PI(3)P, which reside in the plasma membrane and Golgi apparatus. This proteinlipid interaction is mediated in vitro by a positively charged sequence of 19 amino-acid residues located near the Akt phosphorylation site, and is attenuated by Akt phosphorylation (Enomoto et al., 2005) . To elucidate the role of Akt-mediated phosphorylation of Girdin in BTSCs, we attenuated the Akt-Girdin pathway in BTSCs via transfection with a retroviral vector expressing the CT1 domain of Girdin. BTSCs-expressing CT1 diminished the phosphorylation of Girdin and failed to maintain brain tumor stem cell properties. Although the rescue study to overexpress Girdin in Akt-inhibited BTSCs may unveil the role of Akt on Girdin, we were unable to achieve adequate expression of Girdin under the control of a retroviral promoter. The reason for this is unknown, but we speculate that the large size of Girdin cDNA (B6 kb) hindered packaging in retroviruses. These results warrant further studies to elucidate the Akt link to Girdin.
In conclusion, there is increasing evidence that brain malignancies originate from and contain cancer stem Stemness-maintaining function of Girdin in GBM stem cells A Natsume et al cells. We found that Girdin, a novel actin-binding Akt substrate, is required to sustain the stemness functions of these cells in order to facilitate multilineage potential, cell motility, invasion and tumor formation (Figure 6e ). The expression of Girdin is correlated with cancer malignancy and progression, and Girdin requires the maintenance of cancer stem cell properties. These findings suggest that Girdin and its interacting proteins as oncogenes are potential pharmaceutical targets for cancer therapies. Accumulated evidence suggests that Girdin sits at the crossroads of multiple cellular processes, and our appreciation of Girdin function is still in the most nascent of stages. Future work will be required to reveal a comprehensive picture of Girdin function and determine if Girdin is a promising target for glioma therapy.
Materials and methods
GBM stem cells
GBM tissue samples were obtained from patients (no. 0222, no. 0125 and no. 1216) undergoing surgery at the Nagoya University Hospital, Japan, after they provided written informed consent. The procedures used for obtaining BTSCs, namely 0222-and 0125-BTSCs, have been described elsewhere (Yuki et al., 2009) . Briefly, cells were cultured in 5% CO 2 with 20 or 1% oxygen at 37 1C. Cells were dissociated with a Neurocult Chemical Dissociation Kit (Stemcell Technologies, Vancouver, BC, Canada) and then CD 133 þ /À cells were sorted with CD 133/1 Micro Beads (Miltenyi Biotech, Bergisch Gladbach, Germany). The self-renewal activity of established BTSCs was confirmed by the sphere formation from a single cell. To determine whether length of culture had an impact on the amount of Girdin in CD133 þ cells, a GBM tissue obtained from patients no. 1228 and no. 0323 was dissociated, sorted into CD133 þ /-cells, and analyzed immediately (acutely prepared 1228-and 0323-BTSCs).
Antibodies
Rabbit anti-Girdin polyclonal antibody was developed inhouse against the 19 carboxy-terminal amino acids of Girdin and affinity-purified with the immunizing peptide. Other primary antibodies included mouse monoclonal anti-CD133/ 1 (Militenyi Biotec, Bergisch-Gladbach, Germany), rabbit polyclonal anti-Nestin (AB5922, Millipore, Billerica, MA, USA), mouse monoclonal anti-GFAP (Z0334; DAKO, Glostrup, Denmark), mouse monoclonal anti-bIII-Tubulin (TU-20, Millipore), mouse monoclonal anti-Oligodendrocytes (RIP, Millipore), commercial sheep polyclonal anti-Girdin (R&D Biosystem, Minneapolis, MN, USA), rabbit anti-S1416 Stemness-maintaining function of Girdin in GBM stem cells A Natsume et al phosphorylated Girdin (IBL, Gunma, Japan), mouse monoclonal anti-b actin (Sigma-Aldrich, St Louis, MO, USA), polyclonal anti-Akt (Cell Signaling Technology; CST, Danvers, MA, USA), polyclonal anti-phospho-Akt (Ser473) (CST), anti-PTEN (CST), anti-phospho-c-Raf (Ser259)(CST), anti-phospho-GSK-3b (Thr390)(CST), anti-GSK-3b (Transduction Laboratories) and polyclonal anti-GFP (MBL, Nagoya, Japan).
Immunohistochemistry
Immunohistochemical analysis of formalin-fixed paraffinembedded tumor sections and neonatal mouse brain was performed using standard techniques. Antigen retrieval was performed by incubating the tissue in a 0.01 mol/l citrate buffer (pH 6.0) in a microwave oven at 95 1C for 10 min. The section was stained with in-house developed rabbit anti-Girdin polyclonal antibody (1:10 000 dilution) or rabbit anti-S1416 phosphorylated Girdin antibody (1:100), which was followed by staining with biotin-conjugated secondary antibody. We quantified the intensity of Girdin immunostaining. In all five area of a section were randomly selected and positivity was measured by NIH image software.
Immunocytochemistry Dissociated BTSCs were stained with primary anti bodies, including antibodies for nestin, GFAP, bIII-tubulin, oligodendrocytes, Girdin, actin and CD133, after which the corresponding secondary antibody and 4 0 ,6-diamidino-2-phenylindole were added.
Western. blot and immunoprecipitation
Cells were lysed in a buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton-X 100, 20 mM b-glycerophosphate and 1 mM p-amidinophenyl methanesulfonyl fluoride hydrochloride supplemented with Complete TM protease inhibitor cocktail (Roche, Indianapolis, IN, USA) and PhosSTOP TM phosphatase inhibitor cocktail (Roche). The lysates were briefly sonicated and cleared by centrifugation at 12 000 g for 10 min, followed by immunoprecipitation using the indicated antibodies and protein G beads (CST). After washing to remove unbound antibodies, the precipitate was denatured, and the individual proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
The separated proteins were transferred to nitrocellulose membranes, blocked in 4% skim milk in PBS, incubated with primary antibodies and detected using horseradish peroxidaseconjugated secondary antibodies (Dako). In some experiments, the primary antibodies were diluted with CanGet-Signal Solution 1 (Toyobo, Osaka, Japan) to enhance antibody-antigen binding.
RNA interference
Small interfering RNA-mediated knockdown of Girdin was performed as described previously (Enomoto et al., 2005) . The 21-nucleotide synthetic RNA duplexes were obtained from Qiagen (Dusseldorf, Germany). For shRNA-mediated knockdown of Girdin, we synthesized a complementary set of singlestranded oligonucleotides encoding the Girdin target shRNAs (only the sense sequence is shown): shRNA1; 5 0 -GGAA CAAACAAGATTAGAA-3 0 (nucleotides 3837-3755), and shRNA2; 5 0 -GAAGGAGAGGCAACTGGAT-3 0 (nucleotides 4166-4184). The oligonucleotides were directed against a sequence (selected and provided by Dragon Genomics, Shiga, Japan) common to human, mouse and rat Girdin sequences.
The oligonucleotide pair was annealed and inserted into the RNAi-Ready pSIREN-RetroQ vector (Clontech, Palo Alto, CA, USA). To generate retroviral supernatants, GP293-packaging cells were transfected with 12 mg of control or Girdin shRNA-containing pSIREN-RetroQ vector and 12 mg of pVSVG (Clontech) by Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) in 100 mm cell culture dishes containing Opti-MEM medium (Invitrogen) without fetal bovine serum and antibiotics. The medium was replaced 24 h later, and virus-containing supernatants were harvested 48 h post-transfection. To infect the BTSCs with the generated retroviruses, the NeuroCult Chemical Dissociation Kit was used to plate 5 Â 10 4 dissociated cells in six-well plates with neurobasal medium. The plates were precoated with RetroNectin (TAKARA, Otsu, Japan) and mixed with a 1.5 Â 10 5 titer of a 1-ml virus-containing supernatant. Selection was performed using 1 mg/ml puromycin beginning 7 days after transfection. About 2 months later, stable knockdown BTSC clones were generated.
Cell-proliferation assay
The relative cell numbers were determined using a WST-8 cellproliferation assay system, namely, the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). The controlshRNA-expressing BTSCs and Girdin-shRNA-expressing BTSCs were plated at almost the same density into 24-well plates (BD Falcon, San Jose, CA, USA) and maintained at 37 1C in NBE for 14 days. The reagent was added to the wells, and the cultured cells were incubated for 180 min before recording the absorbances at 450 nm and 600 nm using a 2030 ARVO X (Perkin Elmer, Waltham, MA, USA) (n ¼ 5). Formazan dye absorbance was observed at 450 nm, and reference dye absorbance was observed at 600 nm. The percentage of WST-8 activity was represented as the ratio of activity on day (n) to that on day 0.
Tumorsphere-forming assay Single-cell suspensions were plated in 24-well plates (BD Falcon) at 1000 cells/ml. After 10 days, the spheres were counted.
Reverse transcription-polymerase chain reaction (RT-PCR) Total RNA was extracted from cells by using Trizol reagent (Invitrogen). Total RNA (500 ng) was reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche) with the primers listed in Supplementary Table S1 .The PCR products of the lamin A/C gene from the same RNA samples were amplified and served as internal controls. The PCR products were loaded on a 3% agarose gel and stained with ethidium bromide.
Retroviral expression of the Akt-phosphorylation site (CT1 domain) of Girdin For retroviral expression of the CT1 domain of Girdin in BTSCs, the cDNA corresponding to amino acids 1377-1571 of human Girdin was amplified using primers with restriction sites for XhoI and BamHI and introduced into pRetroQAcGFP C1 (Clontech) to generate a fusion protein with AcGFP at the amino terminus. To produce retroviral supernatants, GP2-293-packaging cells were seeded in collagen type I-coated 100 mm cell culture dishes and transfected with the pVSV-G (vesicular stomatitis virus G protein) vector (a gift from K. Hirose, Nagoya University, Japan) and either pRetroQ-AcGFP or pRetroQ-AcGFP-CT1 vector using Lipofectamine 2000 reagent. The medium was replaced 24 h later, and virus-containing supernatants were harvested 48 h post-transfection. The recombinant retrovirus was concentrated by centrifuging the supernatant at 6000 g at 4 1C for 16 h. The concentrated retrovirus was resuspended in PBS overnight at 4 1C and then stored at À80 1C. To monitor the expression of AcGFP and AcGFP-CT1, BTSCs were infected with the retrovirus encoding either AcGFP or AcGFP-CT1, and selected for puromycin (1 mg/ml) resistance.
Modified Boyden-chamber migration assays
The cells were incubated 20 h before the Boyden-chamber assay in a 20 mM Cell Tracker CM-DiI (Invitrogen) solution for 5 min at 37 1C and for an additional 15 min at 4 1C. The filters were coated with a fibronectin (Sigma-Aldrich; dilution 1:40 in PBS) solution and air-dried before use. Migration assays were performed in a modified Boyden chamber with a 24-well HTS Fluoro Blok insert system (BD Falcon). The inserts contain a polyethylene membrane with 8.0-mm pores, which block 99% of the light transmission at wavelengths between 490 and 700 nm. A specific amount (1 Â 10 4 ) of single cells were placed on top of an insert and incubated for 24 h in DMEM containing 1 mg/ml puromycin. The cells were fixed with 4% paraformaldehyde in 0.1 M PBS. The membrane was then cut out of the insert and covered in 4 0 ,6-diamidino-2-phenyl-indole mounting medium (absorption, 360 nm; emission, 460 nm; Vectashield, Vector Laboratories, Burlingame, CA, USA) between two thin coverslips. The total number of migrated cells at the bottom and the non-migrated cells at the top were counted (n ¼ 5). The migration index was calculated by the following formula: number of migrated cells at the bottom/ total number of migrated and nonmigrated cells.
Invasion assay in brain slice model
Female BALB/c nude mice (age, 5 weeks) were decapitated on ice, and their brains were transferred into ice-cold DMEM containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. The brains were mounted on the stage of a vibratome (VT 1000 E, Leica, Wetzlar, Germany) and cut into 300-mm coronal slices, which were transferred onto 30-mm Millicell-CM inserts (pore size, 0.4 mm) (Millipore) in six-well culture plates. The wells contained 1.0 ml DMEM with 10% fetal calf serum. The brain slices were incubated at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 , and the culture medium was replaced with fresh medium twice each week. To allow the slice to remain exposed to the air, the volume of the medium was reduced to 0.8 ml after the second change. This step was critical for the long-term survival of the BTSCs in the slices. A single BTSC sphere labeled with CMDiI or expressing GFP was placed on the brain slice. Fluorescent images were obtained with a stereoscopic fluorescence microscope. Images were captured at 48-h intervals until day 18 using equal-exposure conditions. The images were analyzed with the Developer Toolbox 1.7 software (GE Healthcare, Buckinghamshire, UK) as described . The invasion index was calculated using the following formula: DiI-positive invasion area (B)/initial sphere area (A).
BTSC transplantation model
BTSCs (1 Â 10 3 cells) were stereotactically injected into the frontal lobe of 6-week-old female NOD-SCID mice. The injection coordinates are as follows: 3 mm to the right of the midline, 2 mm anterior to the coronal suture and 3 mm in depth. Mice were inspected daily and the last day of survival was recorded. To identify tumor formation, whole-brain samples were histologically assessed 80-82 days after tumor transplantation.
Statistical analysis
Statistical analysis was performed using one-way and two-way analyses of variance followed by a Bonferroni test to correct for multiple comparisons. Statistical significance was defined as po0.05. Data were expressed as means±s.e.m. Kaplan-Meier plots were compared using the generalized Wilcoxon test.
